Logo Image
Feature|Videos|April 22, 2025

Fully-Connected Continuous Manufacturing™ as the Key to Cost Efficiency and Scalability in Biotech

Innovative Fully-Connected Continuous Manufacturing™ technology and advanced facilities are revolutionizing biomanufacturing and driving cost efficiency, especially in monoclonal antibody production.

During DCAT 2025, Enzene’s Russell Miller discussed the transformative impact of the company’s innovative Fully-Connected Continuous Manufacturing™ technology on the biomanufacturing industry. Miller explained how EnzeneX™ 2.0 technology reshapes the production process and highlighted the strategic significance of Enzene's new state-of-the-art facility in New Jersey.

Key Takeaways:

  • Understand the 'connected' edge that sets Fully-Connected Continuous Manufacturing™ apart from traditional methods.
  • Hear about the strategic impact of Enzene’s new facility in New Jersey.
  • Learn about overcoming the $40 per gram barrier in monoclonal antibody production with EnzeneX™ 2.0.

Related Content